3 results
Approved WMOCompleted
To evaluate BlueWind Medical RENOVATM System safety and performance in OAB patients for extended FU period of 36 months.
Approved WMOPending
To establish the safety and tolerablity of multiple doses of hLF1-11 given once daily for 10 days.
Approved WMORecruiting
Given the limited effectiveness of available EGFR TKIs in patients with NSCLC with EGFR exon 20 insertion mutations, this subset patient population is routinely treated with chemotherapy, similar to patients with no driver mutations (ie, WT EGFR).…